In a move that promises to reshape the landscape of preventative cardiology and sleep medicine, Vivos Therapeutics, Inc. and South Palm Cardiovascular Associates (SPCVA) have officially entered into definitive collaboration and operating agreements. This partnership aims to establish a state-of-the-art regional Sleep & Airway Medicine Center in the heart of Palm Beach County, Florida.
The initiative marks a significant departure from traditional silos in healthcare, creating a physician-aligned management services organization—AIM Florida LLC—which will serve as the engine for integrating advanced obstructive sleep apnea (OSA) diagnostic and treatment protocols directly into a high-volume cardiovascular practice.
Main Facts: A New Paradigm in Patient-Centered Care
The collaboration is built on the shared recognition that cardiovascular health and airway health are intrinsically linked. By forming AIM Florida LLC, Vivos and SPCVA intend to create a streamlined, multi-disciplinary environment where heart health and sleep disorders are managed under one roof.
Under the terms of the agreement, Vivos Therapeutics expects to maintain a 75% majority interest in AIM Florida, pending standard regulatory approvals. The venture is not merely a referral network; it is a clinical infrastructure project designed to address the "compliance gap" that currently plagues the treatment of sleep apnea among cardiac patients.
The planned facility, currently in the final stages of site selection and lease negotiation, is slated to begin operations in the first quarter of 2027. Once fully functional, the center is designed to support a high-throughput model, with an initial capacity to treat approximately 250 patients per month. The operational blueprint allows for rapid scaling, with provisions to add dedicated clinical teams as the patient volume increases.
Chronology: The Path to Integration
The journey toward this partnership began with a shared clinical observation: that a significant portion of the 30,000 patients managed by SPCVA were suffering from undiagnosed or sub-optimally treated obstructive sleep apnea.
- Pre-Partnership Phase: SPCVA leadership identified a critical bottleneck in their workflow. Patients with cardiovascular conditions were frequently referred to external sleep clinics, often resulting in fragmented care, delayed diagnoses, and low patient adherence to traditional CPAP therapies.
- Initial Engagement: Vivos Therapeutics introduced the SPCVA team to their FDA-cleared technology, which encompasses a broader spectrum of diagnostic tools and therapeutic modalities, including specialized oral appliances and myofunctional therapy.
- Agreement Finalization: Following rigorous due diligence and strategic planning, the parties executed definitive operating agreements to formalize the creation of AIM Florida LLC.
- 2025-2026 Development Pipeline: The timeline for the next eighteen months involves site selection, build-out of the specialized facility, and the navigation of local medical licensing and staffing requirements.
- Q1 2027 Launch: The target date for patient intake, signaling the beginning of a coordinated, "one-stop-shop" model for cardiovascular and sleep health in South Florida.
Supporting Data: Why the Cardio-Sleep Link Matters
The necessity for this collaboration is underscored by the overwhelming body of medical evidence linking obstructive sleep apnea to adverse cardiovascular outcomes. According to the American Heart Association and various clinical studies, OSA is an independent risk factor for hypertension, stroke, atrial fibrillation, and heart failure.
SPCVA’s patient population of approximately 30,000 represents a microcosm of the national health crisis. Many of these patients suffer from chronic heart disease, yet their underlying airway issues—which may be exacerbating their cardiac strain—often go unaddressed due to the "watch-and-wait" approach mentioned by SPCVA leadership.
The center will offer a robust menu of evidence-based interventions to bridge this gap:
- Diagnostic Testing: Integrated sleep studies designed to identify severity levels ranging from mild to severe OSA.
- Positive Airway Pressure (PAP) Therapy: Standard-of-care options for patients with severe conditions.
- FDA-Cleared Oral Appliances: A primary focal point of the Vivos approach, offering a viable alternative for patients who struggle with CPAP compliance.
- Advanced Laser Therapy: Emerging treatments that address the physical structure of the airway.
- Myofunctional Therapy: Rehabilitative exercises to strengthen the musculature of the mouth and throat, supporting long-term airway patency.
Official Responses: The Leadership Vision
The motivation behind this partnership is articulated clearly by the leaders of both organizations, who view this as a systemic upgrade to how chronic conditions are managed.
Dr. Andres Ruiz, Leading Cardiologist at SPCVA:
"As cardiologists caring for tens of thousands of chronically ill patients throughout South Florida, we see the impact of obstructive sleep apnea every day," says Dr. Ruiz. He emphasizes that the current standard of care is often insufficient. "We have witnessed the full spectrum—from patients with mild disease who were historically managed with a watch-and-wait approach, to those with severe OSA who struggled to achieve consistent compliance with traditional therapies."
Dr. Ruiz believes that the integration of Vivos’ technology will provide a necessary breakthrough. "When Vivos introduced us to their FDA-cleared approach to OSA testing and treatment, we recognized an important opportunity to address this condition more directly and effectively. We believe that identifying and treating OSA can play a meaningful role in improving our patients’ overall health and outcomes."
R. Kirk Huntsman, Chairman and CEO of Vivos Therapeutics:
For Vivos, this partnership represents the maturation of their business model. "The execution of these definitive agreements is an important milestone in our strategy to partner directly with larger medical specialty groups and support their patients’ sleep and airway needs," Huntsman states.
Huntsman highlights the synergy between Vivos’ tech stack and the established patient trust of a cardiovascular group. "By combining SPCVA’s trusted physician relationships with Vivos’ technology and operating experience, we believe AIM Florida can expand access to OSA care while creating a scalable and capital-efficient model for growth."
Implications: A Model for Future Healthcare Delivery
The launch of the AIM Florida center holds several far-reaching implications for the broader medical community:
1. Reduction of Patient Attrition
One of the most significant challenges in modern medicine is the loss of continuity of care. When a cardiologist refers a patient to a third-party sleep specialist, the patient is often forced to navigate a new set of administrative hurdles, leading to frustration and dropouts. By housing both services under the AIM Florida banner, the partnership aims to keep the patient within a single ecosystem, ensuring that treatment plans are communicated seamlessly between the cardiologist and the sleep specialist.
2. Scalability of the "Medical Specialty Group" Model
If successful, this partnership could serve as a template for other specialty groups—such as endocrinology, neurology, or primary care—to integrate sleep medicine into their own practices. By creating a management services organization (MSO) model, Vivos provides a blueprint that is not only clinically sound but also financially sustainable.
3. Shift Toward Proactive Airway Management
The partnership represents a shift from reactive to proactive care. Rather than waiting for a patient to present with acute sleep apnea symptoms, the SPCVA model encourages universal screening for patients with known cardiovascular risks. This shift could significantly lower long-term medical costs by preventing the exacerbation of heart conditions caused by nighttime oxygen deprivation.
4. Regulatory and Operational Evolution
The requirement for regulatory compliance and the complexity of managing a multi-disciplinary team highlight the evolving nature of healthcare management. Vivos and SPCVA are navigating a complex regulatory environment, and their success will provide valuable data on how specialized medical groups can legally and efficiently expand their scope of practice to improve holistic health outcomes.
Conclusion: A Vision for 2027 and Beyond
As the healthcare industry continues to grapple with the rising prevalence of chronic lifestyle diseases, the partnership between Vivos Therapeutics and South Palm Cardiovascular Associates stands as a testament to the power of integration. By focusing on the intersection of airway health and cardiovascular function, the AIM Florida initiative is poised to set a new standard for patient care in South Florida and beyond.
The countdown to the 2027 opening of the Sleep & Airway Medicine Center is now underway. For the patients of SPCVA, this development offers more than just a new facility; it offers the promise of a more comprehensive, compassionate, and effective approach to their long-term health. Through the convergence of Vivos’ specialized airway expertise and the diagnostic rigor of a leading cardiovascular practice, the future of "whole-patient" care is becoming a reality.
